The innovative drug sector is warming up, and the Sci-Tech Medical ETF Huaxia(588130) has increased by a total of 11.62% in the past week.

As of 14:19 on April 3, 2026, the SSE STAR Market Biopharmaceutical Index (000683) fell 1.90%. Among constituent stocks, performance was mixed: Haoe Bo led the gain with an increase of 3.40%, Huanyu Pharmaceutical rose 2.71%, and Sansheng Guojian rose 0.79%; Chengdu Xian导 led the decline with a drop of 5.39%, Sino Medical Diagnostics fell 4.98%, and Nuowei赞 fell 4.19%. In the past week, the 华夏 科创医药 ETF (588130) has cumulatively gained 11.62%.

On the news front, Rongchang Biopharma’s core product, batoclimab, and vidiz? (vidistug?—as stated) reported 2025 domestic commercialization revenue of RMB 2.27B (+33.67%), with gross margin improving to 84.3%. The selling expense ratio fell by 6.9 percentage points year over year, and profitability quality has continued to improve. The company has already reached a global licensing collaboration between RC148 and AbbVie, receiving an upfront payment of USD 650 million and up to USD 4.95 billion in milestone payments. Batoclimab has also licensed Vor Bio to carry out global development. Together, the two collaborations have a potential total consideration exceeding USD 5 billion, highlighting that its technology platform has been highly recognized by top-tier international pharmaceutical companies.

CITIC Securities noted that in March 2026, innovation drugs saw a strong rebound, mainly benefiting from valuations reverting to relatively low, reasonable levels after an earlier deep pullback. In addition, growth capital switching triggered by the pullback in AI-related tech stocks contributed as well, along with catalysts from head companies delivering on annual report performance and ongoing BD transactions. Currently, A+H listed innovation drug and CXO sectors have entered a period of dense earnings releases. With head companies’ results landing, the sector’s rebound trend has been preliminarily validated. At the same time, key clinical data readouts from AACR 2026 and ASCO 2026 are imminent, and the overseas expansion of domestically developed innovation drugs is accelerating from the “follow-on” stage toward a global leadership stage.

In terms of liquidity, during the trading session, the 华夏 科创医药 ETF rotated 10.19%, with trading volume of RMB 6.2336 million, and market activity remained robust. Looking over a longer period, as of April 2, the average daily trading volume of the 华夏 科创医药 ETF over the past week was RMB 9.4516 million.

According to data, as of March 31, 2026, the top ten weight stocks in the SSE STAR Market Biopharmaceutical Index are: United Imaging Healthcare, BeiGene, i? (艾力斯), Baili Avent? (百利天恒), Rongchang Biopharma, HiTech? (惠泰医疗), Junshi Biosciences, ZeJing? (泽璟制药), BoRui Pharma, and Eir? (奕瑞科技). The combined share of the top ten weight stocks is 48.91%.